proxyvotesnow.com

Home › Companies › Ventyx Biosciences, Inc. › 2025-2026

Ventyx Biosciences, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 02 October 2026.

  • 3Reported items
  • 117Asset managers
  • 311Fund votes
  • 2026-03-03Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Ventyx Biosciences, Inc. in the interactive database Compare manager voting policies

How asset managers voted at the Ventyx Biosciences, Inc. 2025-2026 meeting

Each item below shows how the 117 asset managers that disclosed a Ventyx Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Ventyx Biosciences, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding, advisory basis, the compensation that will or may become payable by Ventyx Biosciences, Inc. to its named executive officers in connection with the merger of merger sub with and into Ventyx Biosciences, Inc.; and

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

99.2% fund support · no official result

FOR 99.1%

The 115 asset managers below cast 99.2% of the shares they voted on this item FOR (32,185,068 for, 242,949 against).

FOR: 32,185,068 (99.1%)AGAINST: 242,949 (0.7%)ABSTAIN: 35,299 (0.1%)NOT VOTED: 1,375 (0.0%)
Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation that will or may become payable by Ventyx Biosc” at Ventyx Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock4,192,4080 00For
Affinity Asset Advisors, LLC3,781,6800 00For
Vanguard3,356,1220 00For
GLAZER CAPITAL, LLC2,745,1750 00For
BAKER BROS. ADVISORS LP2,349,2800 00For
Investment Managers Series Trust II1,047,0850 00For
TIG Advisors, LLC1,027,1130 00For
683 Capital Management, LLC926,8500 00For
Fidelity805,1840 00For
Charles Schwab764,2890 00For
GEODE CAPITAL MANAGEMENT, LLC728,7980 00For
BALYASNY ASSET MANAGEMENT L.P.723,2260 00For
AQR699,0230 00For
Artia Global Partners LP695,9820 00For
State Street588,3800 00For
Connor, Clark & Lunn Investment Management Ltd.584,1270 00For
Woodline Partners LP562,5000 00For
Renaissance504,0360 00For
WATER ISLAND CAPITAL LLC461,1590 00For
Delaware/Macquarie430,0000 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST430,0000 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.427,1260 00For
Magnetar Financial LLC416,6600 00For
ADAR1 Capital Management, LLC412,8730 00For
Dimensional378,7670 00For

Showing the 25 largest of 115 asset managers. See all 115 in the interactive database.

2. TO ADJOURN THE SPECIAL MEETING TO A LATER DATE OR DATES, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE INSUFFICIENT VOTES TO ADOPT THE MERGER AGREEMENT AT THE TIME OF THE SPECIAL MEETING.

CORPORATE GOVERNANCE

97% fund support · no official result

FOR 97%

The 29 asset managers below cast 97% of the shares they voted on this item FOR (9,487,835 for, 286,789 against).

FOR: 9,487,835 (97.1%)AGAINST: 286,789 (2.9%)
Largest asset managers voting on “TO ADJOURN THE SPECIAL MEETING TO A LATER DATE OR DATES, IF NECESSARY OR APPROPRIATE, TO SOLICIT ADDITIONAL PR” at Ventyx Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,909,9120 00For
BlackRock2,814,3020 00For
Investment Managers Series Trust II1,047,0850 00For
Fidelity694,2230 00For
Delaware/Macquarie430,0000 00For
Charles Schwab381,7580 00For
ARBITRAGE FUNDS300,5760 00For
State Street0286,789 00Against
Dimensional246,6190 00For
BRIDGEWAY FUNDS INC129,9000 00For
ALTSHARES TRUST127,6490 00For
American Century107,1300 00For
Goldman Sachs71,7100 00For
ProShares40,9420 00For
PIMCO35,3000 00For
ETFis Series Trust I34,3990 00For
GDL FUND32,3330 00For
Morningstar Funds Trust29,8660 00For
Direxion Shares ETF Trust14,9470 00For
Equitable12,1470 00For
Victory Capital7,2860 00For
Jackson National6,0170 00For
Blackstone Alternative Investment Funds4,2000 00For
Invesco3,8910 00For
SA FUNDS INVESTMENT TRUST2,1320 00For

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

3. To adopt the Agreement and Plan of Merger (as it may be amended from time to time), dated as of January 7, 2026, by and among Eli Lilly and Company, RYLS Merger Corporation ("merger sub"), and Ventyx Biosciences, Inc. (the "merger agreement");

CORPORATE GOVERNANCE

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 28 asset managers below cast 100% of the shares they voted on this item FOR (9,774,300 for, 0 against).

FOR: 9,774,300 (100.0%)
Largest asset managers voting on “To adopt the Agreement and Plan of Merger (as it may be amended from time to time), dated as of January 7, 202” at Ventyx Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,909,9120 00For
BlackRock2,814,3020 00For
Investment Managers Series Trust II1,047,0850 00For
Fidelity694,2230 00For
Delaware/Macquarie430,0000 00For
Charles Schwab381,7580 00For
ARBITRAGE FUNDS300,5760 00For
State Street286,7890 00For
Dimensional246,6190 00For
BRIDGEWAY FUNDS INC129,9000 00For
ALTSHARES TRUST127,6490 00For
American Century107,1300 00For
Goldman Sachs71,7100 00For
ProShares40,9420 00For
PIMCO35,3000 00For
ETFis Series Trust I34,3990 00For
GDL FUND32,3330 00For
Morningstar Funds Trust29,8660 00For
Direxion Shares ETF Trust14,9470 00For
Equitable12,1470 00For
Victory Capital7,2860 00For
Jackson National6,0170 00For
Blackstone Alternative Investment Funds4,2000 00For
Invesco3,8910 00For
SA FUNDS INVESTMENT TRUST2,1320 00For

Showing the 25 largest of 28 asset managers. See all 28 in the interactive database.

Largest Ventyx Biosciences, Inc. shareholders voting in 2025-2026

Ranked by the number of Ventyx Biosciences, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 71,358,638 shares outstanding at the time of that meeting.

Top Ventyx Biosciences, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 5.88%
2Affinity Asset Advisors, LLC 5.30%
3Vanguard 4.70%
4GLAZER CAPITAL, LLC 3.85%
5BAKER BROS. ADVISORS LP 3.29%
6Investment Managers Series Trust II 1.47%
7TIG Advisors, LLC 1.44%
8683 Capital Management, LLC 1.30%
9Fidelity 1.13%
10Charles Schwab 1.07%

Reported Ventyx Biosciences, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Ventyx Biosciences, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Bank of America Corporation 6.47% DEF14A
Entities affiliated with Point72 Asset Management, L.P. 6.17% DEF14A
Raju Mohan 6.15% 13D
Morgan Stanley 6.02% 13F
Entities affiliated with Citadel Advisors LLC 6.00% DEF14A
Somasundaram Subramaniam, M.B.A. 5.78% DEF14A
Entities affiliated with New Science Ventures 5.65% DEF14A
Vanguard Group 5.53% 13F
BlackRock, Inc. 5.35% DEF14A
Sheila Gujrathi, M.D. 1.71% DEF14A

Percentages above are of 71,358,638 shares outstanding, as reported by Ventyx Biosciences, Inc. on its Form 10-Q dated 2025-11-03 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ventyx Biosciences, Inc.’s 10-Q dated 2025-11-03. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Ventyx Biosciences, Inc.'s shareholder meeting held 2026-03-03, in the 2025-2026 proxy season, 117 asset managers reported how they voted in their SEC Form N-PX filings, covering 311 separate fund positions. Their filings are grouped here into 3 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To approve, on a non-binding, advisory basis, the compensation that will or may become payable… — the reporting funds cast 99.2% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Ventyx Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).